Literature DB >> 16183519

Smallpox vaccine and its stockpile in 2005.

Isao Arita1.   

Abstract

Smallpox vaccine was the most important tool in the successful eradication of smallpox. In 1980, this achievement made it possible for all nations to cease smallpox vaccination. However, the threat of smallpox bioterrorism has made it necessary to reconsider the need for vaccination. Over the past 3 years, many nations have set up action plans for use in the event of such an attack. The setting up of these plans was not simple. Several factors needed to be considered, including the judgement of risk, vaccine complications, conventional vaccines versus new vaccines, optimal stockpile of smallpox vaccine, and its use for different target populations in different emergency situations. Here, I review measures taken by the USA, Japan, and other nations, and discuss likely national and global efforts in 2005 and subsequently, in view of the fact that half of the world's population is now apparently unvaccinated and that this proportion will increase with time.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16183519     DOI: 10.1016/S1473-3099(05)70242-5

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  5 in total

1.  Human antibody responses to the polyclonal Dryvax vaccine for smallpox prevention can be distinguished from responses to the monoclonal replacement vaccine ACAM2000.

Authors:  Christine Pugh; Sarah Keasey; Lawrence Korman; Phillip R Pittman; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2014-04-23

Review 2.  Smallpox vaccines for biodefense.

Authors:  Richard B Kennedy; Inna Ovsyannikova; Gregory A Poland
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

Review 3.  The development of global vaccine stockpiles.

Authors:  Catherine Yen; Terri B Hyde; Alejandro J Costa; Katya Fernandez; John S Tam; Stéphane Hugonnet; Anne M Huvos; Philippe Duclos; Vance J Dietz; Brenton T Burkholder
Journal:  Lancet Infect Dis       Date:  2015-02-06       Impact factor: 25.071

4.  A Critical Analysis of the Scientific and Commercial Rationales for the De Novo Synthesis of Horsepox Virus.

Authors:  Gregory D Koblentz
Journal:  mSphere       Date:  2018-03-07       Impact factor: 4.389

Review 5.  Recent advances in the study of live attenuated cell-cultured smallpox vaccine LC16m8.

Authors:  Akiko Eto; Tomoya Saito; Hiroyuki Yokote; Ichiro Kurane; Yasuhiro Kanatani
Journal:  Vaccine       Date:  2015-08-28       Impact factor: 4.169

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.